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Purpose: To assess time to ﬁrst achievement of clinically signiﬁcant visual acuity (VA) gains from baseline in
patients with retinal vein occlusion (RVO) receiving ranibizumab versus sham treatment.
Design: Post hoc analyses of 2 phase 3 clinical trials assessing efﬁcacy and safety of ranibizumab in patients
with branch RVO (Ranibizumab for the Treatment of Macular Edema following Branch Retinal Vein Occlusion:
Evaluation of Efﬁcacy and Safety [BRAVO] study; NCT00061594) and central RVO (Ranibizumab for the Treat-
ment of Macular Edema after Central Retinal Vein Occlusion Study: Evaluation of Efﬁcacy and Safety [CRUISE];
NCT00056836) over 12 months.
Participants: Seven hundred eighty-nine patients (BRAVO, n ¼ 397; CRUISE, n ¼ 392).
Intervention: Randomization to monthly intraocular ranibizumab injections (0.3 mg/0.5 mg) or sham. After 6
monthly injections (treatment period), patients meeting prespeciﬁed criteria received as-needed (pro re nata
[PRN]) ranibizumab at their assigned dose (sham patients, ranibizumab 0.5 mg) through month 12 (observation
period). BRAVO patients meeting speciﬁc eligibility criteria could receive rescue laser treatment once during the
treatment and once during the observation periods.
Main Outcome Measures: Time to ﬁrst gain of 15 letters or more from baseline, analyzed using Kaplan-Meier
methods. To evaluate the effect of delaying ranibizumab treatment, sham patients’ VA data also were analyzed,
with month 6 considered as baseline to assess vision gains during the 6 months of receiving ranibizumab PRN.
Results: Median time to ﬁrst 15-letter or more gain from baseline was 12.0 (sham), 4.8 (ranibizumab 0.3 mg),
and 4.0 months (ranibizumab 0.5 mg) in BRAVO and 12.2, 5.9, and 5.2 months, respectively, in CRUISE. The
cumulative proportion of patients who had ever gained 15 letters or more from baseline by month 12 was 50%
(sham), 68% (ranibizumab 0.3 mg), and 71% (ranibizumab 0.5 mg) in BRAVO and 42%, 61%, and 66%,
respectively, in CRUISE. After 6 months of ranibizumab PRN treatment, a cumulative 10.8% (BRAVO) and 26.2%
(CRUISE) of initially sham-treated patients ever gained 15 letters or more.
Conclusions: This retrospective analysis shows that more than 50% of patients treated with monthly ranibi-
zumab achieved clinically signiﬁcant vision gains during the initial 6 months of treatment, which largely were main-
tained using PRN treatment to 12 months. In comparison, less than 50% of patients initially randomized to sham (and
later receiving ranibizumab 0.5 mg PRN treatment) ever achieved clinically signiﬁcant vision gains. These results
suggest that initiating treatment immediately after diagnosis may provide the greatest vision gains. The potential
beneﬁts of early treatment should be evaluated further in prospective clinical studies.Ophthalmology 2014;121:1059-
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Open access under CC BY-NC-ND license.Retinal vein occlusions (RVOs) are the second most common
cause of retinal vascular disease after diabetic retinopathy.1
Retinal vein occlusions are classiﬁed as either branch RVO
(BRVO) or central RVO (CRVO), depending on the
location of the occlusion.1 There are approximately 180 000
cases of RVO in the United States each year, and most of
these (approximately 150 000 per year) are BRVOs.2
Although CRVOs represent a smaller proportion of RVO
cases overall (approximately 30 000 per year),2 they are 2014 by the American Academy of Ophthalmology
Published by Elsevier Inc.Open access under CC BY-NC-ND license.more likely to lead to severe vision loss and are associated
with a high risk of vitreous hemorrhage and neovascular
glaucoma.2e4
The Ranibizumab for the Treatment of Macular Edema
following Branch Retinal Vein Occlusion: Evaluation of Ef-
ﬁcacy and Safety (BRAVO) study and the Ranibizumab for
the Treatment of Macular Edema after Central Retinal Vein
Occlusion Study: Evaluation of Efﬁcacy and Safety (CRUISE)
were randomized, placebo-controlled, phase 3 clinical trials1059http://dx.doi.org/10.1016/j.ophtha.2013.11.022
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Ophthalmology Volume 121, Number 5, May 2014designed to evaluate the efﬁcacy and safety of monthly in-
jections of ranibizumab 0.3 mg or 0.5 mg in patients with
BRVO (BRAVO) or CRVO (CRUISE) compared with
sham.5,6 In both studies, patients received monthly ranibizu-
mab at their assigned dose for an initial 6-month period
(treatment period). This was followed by a 6-month observa-
tion period where ranibizumab at the assigned dose was
administered as needed (pro re nata [PRN]) based on speciﬁc
retreatment criteria.5,6 In the BRAVO study, rescue laser
treatment also could be administered once during the treatment
period and once during the observation period for all patients
who met prespeciﬁed eligibility criteria. Patients in both
studies who received sham during the treatment period were
eligible to receive 0.5 mg ranibizumab PRN during the
observation period.
During the initial 6-month treatment period, rapid and
sustained signiﬁcant improvements in visual acuity (VA)
versus sham were seen in the 0.3-mg and 0.5-mg dose
groups in both BRAVO and CRUISE as early as day 7, and
these were maintained through 12 months.5,6 During the
6-month observation period, treatment with ranibizumab
PRN generally maintained, on average, the visual and
anatomic beneﬁts achieved during the 6-month treatment
period in both studies.7,8 Patients who initially received
sham treatment demonstrated improvements in both
anatomic and visual outcomes at month 12, but vision gains
were not as great as those in the 2 groups initially ran-
domized to ranibizumab.7,8 Results from these 2 studies led
to United States Food and Drug Administration approval of
ranibizumab for treatment of macular edema after BRVO
and CRVO.
This post hoc analysis of data from BRAVO and CRUISE
was designed to examine further the response to ranibizumab
treatment and to assess the time for patients to achieve clin-
ically signiﬁcant VA gains from baseline, deﬁned as an in-
crease in VA from baseline of 15 letters or more, after
ranibizumab treatment in patients with macular edema sec-
ondary to RVO. In addition, the analysis explored the treat-
ment response of patients in the sham groups who received
ranibizumab PRN treatment at least 6 months after a diag-
nosis of BRVO or CRVO and the association of VA out-
comes with central foveal thickness (CFT) measurements.Methods
Study Design
This was a post hoc analysis of data from 2 phase 3, multicenter,
randomized, double-masked, sham injectionecontrolled clinical
trials designed to evaluate the efﬁcacy and safety of intraocular
injections of ranibizumab in patients with macular edema after
BRVO (BRAVO trial) or CRVO (CRUISE). The details of the
study design and methods for both BRAVO and CRUISE have
been published elsewhere5,6 but are described brieﬂy here.
Both studies were of 12 months’ duration, comprising a
6-month, sham injectionecontrolled treatment period, with patients
receiving either ranibizumab (0.3 or 0.5 mg) administered monthly
or a monthly sham injection, and a 6-month observation period
in which the ranibizumab treatment groups could continue to
receive their assigned treatment PRN. During the observation
period, those patients previously receiving sham could receive10600.5 mg ranibizumab. Patients were monitored monthly during the
observation phase, and ranibizumab was administered based on
prespeciﬁed treatment criteria, speciﬁcally, if the investigator-
assessed study eye Snellen equivalent best-corrected VA (BCVA)
was worse than 20/40 based on the Early Treatment Diabetic
Retinopathy Study (ETDRS) chart or if mean central subﬁeld
thickness (CST) was more than 250 mm according to time-domain
optical coherence tomography (Zeiss Stratus 3; Carl Zeiss Meditec,
Inc., Dublin, CA).
Patients enrolled in the BRAVO trial who had a BCVA of
20/40 or worse (Snellen equivalent) or a mean central subﬁeld
thickness of 250 mm or more and, when compared with the visit 3
months before the current visit, had either a BCVA gain of fewer
than 5 letters or a decrease in CFT of less than 50 mm were eligible
for laser treatment once during the treatment period and once
during the observation period, beginning at months 3 and 9,
respectively.6,7
The protocols for the BRAVO and CRUISE studies were
approved by the institutional review board at each study site, and both
studies were conducted according to the International Conference on
Harmonization E6 Guideline for Good Clinical Practice and any na-
tional requirements. Both studies are registered at ClinicalTrials.gov
(BRAVO, NCT00486018; CRUISE, NCT00485836), and all patients
provided informed consent before participation in the study.
Patients
Eligible patients were 18 years of age or older with macular edema
involving the foveal center after BRVO or CRVO diagnosed within
12 months of screening, with a Snellen-equivalent BCVA of 20/40
to 20/400 (BRAVO study) or 20/40 to 20/320 (CRUISE study) in
the study eye and mean CST of 250 mm or more (assessments at
both screening and day 0). Patients were randomized 1:1:1 to
receive monthly ranibizumab 0.3 or 0.5 mg for 6 months or monthly
sham injections. The randomization was stratiﬁed by study center
and baseline BCVA of 34 letters or fewer (approximate Snellen
equivalent, worse than 20/200), 35 to 54 letters (approximate
Snellen equivalent, 20/200eworse than 20/80), and 55 letters or
more (approximate Snellen equivalent, better than 20/80). One eye
was chosen as the study eye; if both eyes were eligible, the eye with
the worst BCVA at screening was selected. Patients in BRAVO also
were eligible to receive rescue laser treatment, as described above.
Outcome Measures
The primary efﬁcacy outcome in BRAVO and CRUISE was the
mean change from baseline in BCVA letter score at month 6. The
percentage of patients who gained 15 letters or more, the per-
centage of patients who had a Snellen equivalent of 20/40 or
better, and the mean change from baseline in CFT were sec-
ondary efﬁcacy outcomes. This post hoc analysis examined the
time to ﬁrst achieving a clinically signiﬁcant gain in BCVA in
the study eye, deﬁned as an increase in BCVA of 15 ETDRS
letters or more from baseline. In addition, the time to ﬁrst
achieving a 10-letter or more gain and the time to ﬁrst achieving
a Snellen equivalent of 20/40 or better in study eyes with vision
worse than 20/40 at baseline were evaluated. The relationship
between visual gain and changes in CFT also was assessed. To
examine the effect of delaying treatment, vision gains from
month 6 in the sham arm were assessed (using month 6 as
baseline), starting from when sham patients were eligible to cross
over to ranibizumab 0.5 mg PRN. Patients were evaluated
monthly with a complete eye examination, optical coherence
tomography, measurement of vital signs, review of medical
history including concomitant medications and concurrent ocular
procedures, and safety assessments.
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Analyses in both studies were based on the intent-to-treat population,
with patients grouped according to their treatment assignment. Time to
achieve vision gains (gains of15 or10 ETDRS letters vs. baseline)
and the time to achieve a Snellen equivalent of 20/40 or better in study
eyes with vision worse than 20/40 at baseline were analyzed using
Kaplan-Meier methods. The log-rank test was used to compare the
distribution of the time to end points between treatment groups. Gains
in vision required a second conﬁrmatory visit: visual gains had to be
maintained for at least 2 consecutive visits, except for those seen at the
last visit. To assess the extent of the relationship between CFT and VA
over time, changes in CFT from baseline versus changes in VA from
baseline and the absolute CFT versus absolute VA values were
correlated using Pearson’s correlation coefﬁcient.
For the analysis of the sham crossover patients, VA values at
the end of the treatment period (month 6) were used as baseline for
the subsequent crossover period. Subsequent gains in vision for
each patient were measured versus these new baseline values.
Observed BCVA values were used in all analyses.
Results
Patients
In the BRAVO study, 397 patients were randomized to receive
intraocular injections of 0.3 mg ranibizumab (n ¼ 134), 0.5 mgTable 2. Treatment during the Ranibizumab for the Treatment of Macu
Efﬁcacy and Safety Study and the Ranibizumab for the Treatment
Evaluation of Efﬁc
Characteristics by Study Sh
BRAVO
No. of patients
Months from RVO diagnosis to screening
Mean (SD)
Range
Mean no. of injections per patient*
Treatment period
Observation periody
Patients receiving ﬁrst as-needed injection at month 6, n (%)y
Rescue laser treatment, n (%)z
Treatment period
Observation periody
CRUISE
No. of patients
Months from RVO diagnosis to screening
Mean (SD)
Range
Mean no. of injections per patient*
Treatment period
Observation periody
Patients receiving ﬁrst as-needed injection at month 6, n (%)y
BRAVO ¼ Ranibizumab for the Treatment of Macular Edema following B
(NCT00061594); CRUISE ¼ Ranibizumab for the Treatment of Macular Edem
Safety (NCT00056836); RVO ¼ retinal vein occlusion; SD ¼ standard deviat
*During the 6-month treatment period (day 0 to month 5), sham patients receiv
sham patients received 0.5 mg ranibizumab if they met prespeciﬁed criteria.
yMeans and percentages are based on the number of patients who completed mo
and 125 patients (0.5 mg); CRUISE, 115 patients (sham), 129 patients (0.3 m
zPatients could receive rescue laser treatment once during the 6-month treatm
prespeciﬁed criteria.ranibizumab (n ¼ 131), or sham injections (n ¼ 132), whereas in
CRUISE, 392 patients were randomized to receive intraocular in-
jections of 0.3 mg ranibizumab (n ¼ 132), 0.5 mg ranibizumab
(n ¼ 130), or sham injections (n ¼ 130). Patient baseline de-
mographic characteristics were similar across treatment groups in
both studies (data not shown).5,6 Baseline ocular characteristics
also were similar across treatment groups in the 2 studies5,6; key
baseline ocular characteristics are summarized in Table 1 (available
at www.aaojournal.org).
Approximately 95% of enrolled patients in BRAVO completed
the study through month 6, and 90% completed the study through
month 12, whereas in CRUISE, approximately 89% and 85% of
patients, respectively, completed the study. The mean number of
injections administered to patients in the 2 studies during the initial
6-month treatment period was between 5.4 and 5.8 (Table 2).
During the observation period, in patients who completed the
initial 6-month treatment period, 87% of sham-treated patients in
BRAVO and 85% of sham-treated patients in CRUISE received
ranibizumab 0.5 mg PRN. Patients in these sham crossover groups
received a mean of 3.8 (BRAVO) and 4.2 (CRUISE) injections
during the 6-month observation period (Table 2). In the BRAVO
study, this was higher than that for the 2 ranibizumab groups
during the observation period, but in CRUISE, the number of
injections in the 3 groups, although still numerically lower in the
ranibizumab groups, was comparable. In both studies, a higher
proportion of sham crossover patients required their ﬁrst
ranibizumab 0.5-mg PRN injection at month 6 (the start of thelar Edema following Branch Retinal Vein Occlusion: Evaluation of
of Macular Edema after Central Retinal Vein Occlusion Study:
acy and Safety
am (Plus 0.5 mg Ranibizumab)
Ranibizumab
0.3 mg 0.5 mg
132 134 131
3.7 (3.7) 3.6 (4.1) 3.3 (3.1)
0e16 0e35 0e13
5.5 5.7 5.7
3.8 2.9 2.8
104 (84.6) 55 (43.0) 50 (40.0)
76 (57.6) 27 (20.1) 28 (21.4)
31 (25.2) 41 (32.0) 31 (24.8)
130 132 130
2.9 (2.9) 3.6 (3.2) 3.3 (3.7)
0e14 0e12 0e27
5.4 5.8 5.5
4.2 3.9 3.6
100 (87.0) 74 (57.4) 64 (53.8)
ranch Retinal Vein Occlusion: Evaluation of Efﬁcacy and Safety study
a after Central Retinal Vein Occlusion Study: Evaluation of Efﬁcacy and
ion.
ed sham injections; during the 6-month observation period (months 6e11),
nth 6 in each study: BRAVO, 123 patients (sham), 128 patients (0.3 mg),
g), and 119 patients (0.5 mg).
ent period and once during the 6-month observation period if they met
1061
Figure 1. Graphs showing time to ﬁrst gain of 15 letters or more from baseline in the Ranibizumab for the Treatment of Macular Edema following Branch
Retinal Vein Occlusion: Evaluation of Efﬁcacy and Safety (BRAVO) study and the Ranibizumab for the Treatment of Macular Edema after Central Retinal
Vein Occlusion Study: Evaluation of Efﬁcacy and Safety (CRUISE). A gain of 15 letters or more was conﬁrmed at the next visit or occurred at the last
qualifying visit. The median time to ﬁrst achieving a 15-letter or more gain from baseline in the BRAVO study was 12 months (sham), 4.8 months (0.3 mg
ranibizumab), and 4 months (0.5 mg ranibizumab); in CRUISE it was 12.2 months (sham), 5.9 months (0.3 mg ranibizumab), and 5.2 months (0.5 mg
ranibizumab). BRAVO comparisons over 12 months: 0.5 mg vs. sham, P< 0.0001 (log-rank test); 0.3 mg vs. sham, P< 0.0001 (log-rank test). CRUISE
comparisons over 12 months: 0.5 mg vs. sham, P<0.0001 (log-rank test); 0.3 mg vs. sham, P< 0.0001 (log-rank test).
Ophthalmology Volume 121, Number 5, May 2014observation period) compared with the ranibizumab-treated groups
(Table 2). Rescue laser treatment was required by more than twice
as many patients in the sham group during the treatment period of
BRAVO compared with the 2 ranibizumab groups, but during the
observation period, the percentages were very similar for all 3
treatment groups (Table 2).Figure 2. Graphs showing time to ﬁrst gain of 15 letters or more after sham pati
the Treatment of Macular Edema following Branch Retinal Vein Occlusion: Eva
Treatment of Macular Edema after Central Retinal Vein Occlusion Study: Evalu
gain of 15 letters or more was conﬁrmed. Sham patients could cross over to rece
were based on sham crossover patients with observed best-corrected visual acui
1062Visual Outcomes
The time to ﬁrst gain of 15 letters or more over the 12-month study
period is shown in Figure 1 for BRAVO and CRUISE. The median
time to ﬁrst 15-letter gain or more in the ranibizumab 0.3-mg and
0.5-mg groups was 4.8 and 4.0 months in BRAVO and 5.9 and 5.2ents crossed over to ranibizumab pro re nata (PRN) in the Ranibizumab for
luation of Efﬁcacy and Safety (BRAVO) study and the Ranibizumab for the
ation of Efﬁcacy and Safety (CRUISE), using month 6 (M6) as baseline. A
ive 0.5 mg ranibizumab starting from M6. The mean number of injections
ty (BCVA) in the study eye at M6.
Figure 4. Graphs showing time to ﬁrst achievement of 20/40 or better vision among patients with vision worse than 20/40 vision at baseline in the
Ranibizumab for the Treatment of Macular Edema following Branch Retinal Vein Occlusion: Evaluation of Efﬁcacy and Safety (BRAVO) study and the
Ranibizumab for the Treatment of Macular Edema after Central Retinal Vein Occlusion Study: Evaluation of Efﬁcacy and Safety (CRUISE). Achievement
of 20/40 or better vision was conﬁrmed at the next visit or occurred at the last qualifying visit. The median time to ﬁrst achieving 20/40 or better vision from
baseline was as follows: BRAVO, 8 months (sham), 3.1 months (0.3 mg ranibizumab), and 3.7 months (0.5 mg ranibizumab); CRUISE, 12.4 months (sham),
11.9 months (0.3 mg ranibizumab), and 7 months (0.5 mg ranibizumab). BRAVO comparisons over 12 months: 0.5 mg vs. sham, P ¼ 0.003 (log-rank test);
0.3 mg vs. sham, P ¼ 0.0006 (log-rank test). CRUISE comparisons over 12 months: 0.5 mg vs. sham, P ¼ 0.0001 (log-rank test); 0.3 mg vs. sham, P ¼
0.0045 (log-rank test).
Thach et al  Ranibizumab for RVOmonths in CRUISE, respectively. By month 6, more than 50% of
patients in the ranibizumab groups in both studies had ever gained
15 letters or more (Fig 1). Many of these patients ﬁrst achieved this
gain in vision by month 1. By comparison, the median time to ﬁrst
15-letter or more gain was greater in the sham groups in BRAVO
and CRUISE (12.0 and 12.2 months, respectively). The distribu-
tions of the time to ever achieving a 15-letter gain or more over the
12-month analysis period were signiﬁcantly different between the
ranibizumab dose groups and the sham group (P< 0.0001 for both
0.3 and 0.5 mg compared with sham in BRAVO and CRUISE).
The cumulative proportion of patients who had ever gained 15
letters or more over the 12-month study period was 71% (ranibi-
zumab 0.5 mg), 67.8% (ranibizumab 0.3 mg), and 49.9% (sham/
0.5 mg) in the BRAVO study and 66.4% (0.5 mg ranibizumab),
60.9% (0.3 mg ranibizumab), and 41.7% (sham/0.5 mg) in
CRUISE. When the sham plus 0.5-mg ranibizumab crossover
group was analyzed using month 6 data as baseline to assess visual
gains during their ﬁrst 6 months of receiving ranibizumab (i.e.,
during the observation period), the median time to ﬁrst 15-letter
gain or more could not be estimated because the cumulative per-
centage of patients initially treated with sham who ever gained 15
letters or more during the observation period was less than 50%.
The cumulative percentage of patients previously treated with
sham ever gaining 15 letters or more from month 6 to month 12
was 10.8% in BRAVO and 26.2% in CRUISE (Fig 2).
Results were similar when the time to a ﬁrst gain of 10 ETDRS
letters or more from baseline was assessed. Shorter median times to
the ﬁrst gain of 10 ETDRS letters or more were observed in the
ranibizumab groups than in the sham plus 0.5 mg ranibizumab
groups, although the median time to a ﬁrst gain of 10 letters or
more from baseline was shorter compared with the 15-letter or
more gain, and a higher cumulative proportion of patients in each
treatment group had achieved this end point over the 12-month
study period (Fig 3A, available at www.aaojournal.org). Thedistributions of the time to ﬁrst gain of 10 ETDRS letters or
more were signiﬁcantly different between the ranibizumab dose
groups and the sham group (P< 0.0001 for both 0.3 and 0.5 mg
ranibizumab compared with sham treatment in BRAVO and
CRUISE) over the 12-month analysis period. In a similar anal-
ysis of patients in the sham plus 0.5 mg ranibizumab crossover
group using month 6 as baseline, the median time to ﬁrst gain of 10
ETDRS letters or more could not be estimated because cumula-
tively less than 50% of the patients initially treated with sham who
received ranibizumab for the ﬁrst time during the observation
period had ever achieved a 10-letter or more gain within the 6
months of PRN treatment. In contrast, more than 50% of patients in
the ranibizumab groups had achieved a 10-letter or more gain
within 3 months of ﬁrst receiving monthly ranibizumab treatment
(Fig 3, available at www.aaojournal.org).
In patients with vision worse than 20/40 at baseline, the median
time to achieve 20/40 vision or better from baseline was 8.0, 3.1,
and 3.7 months in the BRAVO study and 12.4, 11.9, and 7.0
months in CRUISE in the sham, ranibizumab 0.3-mg, and ranibi-
zumab 0.5-mg groups, respectively. Over the 12-month study
period, cumulatively approximately 70% of patients treated with
monthly ranibizumab in BRAVO and 50% in CRUISE had
improved vision to 20/40 or better from baseline (Fig 4). As with
10- and 15-letter improvement in BCVA, the 2 doses had a very
similar effect; there was no statistical difference in the ability to
achieve 20/40 or better vision in either the BRVO or CRVO
groups. A lower cumulative proportion of patients initially treated
with sham in both studies achieved 20/40 or better vision from
baseline, despite the sham-treated patients receiving ranibizumab
0.5 mg PRN during the observation period (Fig 4). Again, the
distributions of the time to ﬁrst achievement of 20/40 vision or
better were signiﬁcantly different between the ranibizumab dose
groups and the sham groups over the 12-month analysis period
in both BRAVO and CRUISE.1063
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Foveal Thickness
In both BRAVO and CRUISE, there was a trend for lower absolute
CFT values to be associated with higher VA scores, and there was
also a trend toward improvements in VA from baseline being
associated with reductions in CFT from baseline (Figs 5 and 6,
available at www.aaojournal.org). This trend appeared stronger at
month 6 than month 12. However, VA improvements were not
accompanied by improvements in CFT in all cases, whereas
some patients who had large CFT values may have had high VA
scores or vice versa.Discussion
Gains in vision of 15 or more ETDRS letters are considered
clinically signiﬁcant because they represent a doubling of
the visual angle, are considered meaningful by regulatory
authorities, and correspond to a clinically meaningful im-
provement in scores on the 25-item National Eye Institute
Visual Function Questionnaire, which was developed to
measure patients’ perception of vision-related function.9
In the BRAVO and CRUISE phase 3 pivotal studies, the
percentage of patients who gained 15 letters or more from
baseline at month 12 was 56.0%, 60.3%, and 43.9% in
BRAVO and 47.0%, 50.8%, 33.1%, in CRUISE in the
ranibizumab 0.3 mg, ranibizumab 0.5 mg, and sham plus 0.5
mg ranibizumab groups, respectively.7,8 This post hoc
analysis of the BRAVO and CRUISE studies further shows
that the median time to ﬁrst gaining 15 letters or more from
baseline was signiﬁcantly shorter with ranibizumab 0.3-mg
or 0.5-mg treatment when compared with the sham plus
0.5 mg ranibizumab group. More than half of the patients in
the ranibizumab groups had ﬁrst gained 15 letters or more
from baseline within 6 months of starting monthly treat-
ment, whereas it took 12 months or more for half of the
patients in the sham plus 0.5 mg ranibizumab groups to
achieve a ﬁrst 15-letter gain or more from baseline. Sub-
sequent criteria-based treatment with ranibizumab PRN
during the observation period resulted in a small increase in
the proportion of patients ever achieving a 15-letter or more
visual gain at some point between months 6 and 12. By the
end of the studies (month 12), between 60% and 71% of
patients initially randomized to ranibizumab 0.3 or 0.5 mg
had ever gained 15 letters or more from baseline. These
results, in conjunction with the percentage of patients who
had gained 15 letters or more from baseline at month 12,
suggest that most of the ﬁrst 15-letter or more gains in the
ranibizumab groups were maintained over the observation
period with PRN treatment.
Patients who initially received sham treatment also
showed some improvements in vision during the initial
6-month treatment period. The cumulative proportions of
sham-treated patients achieving VA gains of 15 letters or
more by month 6 was 14% in CRUISE and 27% in
BRAVO; however, these gains were substantially lower
than those for the ranibizumab-treated patients. Some of the
vision gains observed in the BRAVO sham group may be
the result of rescue laser treatment,6 whereas the remainder
of the gains, as well as those seen in CRUISE, are likely to1064be the result of spontaneous improvement.10,11 During the
observation period, when sham patients were eligible to
receive ranibizumab 0.5 mg PRN, the cumulative proportion
of patients ever achieving a 15-letter or more gain increased;
however, in both BRAVO and CRUISE, these sham
crossover groups did not perform as well as the groups that
received ranibizumab from the start of the studies, and by
month 12, the cumulative proportion of sham-treated pa-
tients ever achieving a gain in vision of 15 letters or more
remained lower than in the ranibizumab-treated groups.
Similar results were seen when the time to achieve better
than 20/40 vision during treatment in patients with worse
than 20/40 vision at baseline was analyzed. The median time
to achieve 20/40 or better vision was signiﬁcantly shorter in
the ranibizumab groups than in the sham plus 0.5 mg
ranibizumab groups. In the BRAVO study, the median time
to ﬁrst achievement of 20/40 vision or better from baseline
was within 4 months in the ranibizumab groups, whereas it
took twice as long (8 months) in the sham plus 0.5 mg
ranibizumab group. In CRUISE, the median time to ﬁrst
achievement of 20/40 vision or better was longer in all arms
when compared with the BRAVO study: 7 months in the 0.5
mg ranibizumab group, 11.9 months in 0.3 mg ranibizumab
group, and 12.4 months in sham plus 0.5 mg ranibizumab
group. Over the 12-month study period, the cumulative
percentage of ranibizumab-treated patients ever achieving
20/40 vision or better was approximately 70% in BRAVO
and more than 50% in CRUISE and was substantially lower
in sham-treated patients, despite receiving ranibizumab 0.5
mg PRN in the observation period. These results, together
with the percentage of patients with 20/40 vision or better at
month 12 (approximately 67% in BRAVO and 43% in
CRUISE in the ranibizumab treatment groups),7,8 suggest
that most of these vision gains were maintained at month 12.
Attaining 20/40 vision or better is an important beneﬁt with
signiﬁcant implications for patient quality of life because
vision of 20/40 or better in at least 1 eye represents the
minimum standard for obtaining a driver’s license across
most of the United States.12 In a recent post hoc analysis
of patients with age-related macular degeneration,13
ranibizumab treatment was shown to preserve or improve
self-reported driving status and slowed or reversed de-
clines in the mean 25-item National Eye Institute Visual
Function Questionnaire driving subscale score. Based on the
analysis here, similar beneﬁts for patients with RVO may be
expected.
In both the BRAVO and CRUISE studies, patients in the
sham crossover groups were not eligible to receive ranibi-
zumab 0.5 mg PRN until the start of the observation period.
To assess the response to ranibizumab in these patients after
what was effectively a 6-month delay in starting treatment,
the sham groups in both studies also were analyzed using
month 6 as baseline. Visual acuity values for the sham-treated
patients at the end of the treatment period (month 6) were
taken as the new baseline values against which subsequent
vision gains during the 6-month PRN treatment with ranibi-
zumab 0.5 mg were assessed. This approach allowed direct
comparison of gains in vision in the sham crossover group
during initial ranibizumab treatment between months 7 and
12 with those of the monthly ranibizumab treatment groups
Thach et al  Ranibizumab for RVOduring their initial 6-month treatment period immediately
after randomization. The results from this analysis showed
that the sham patients in both BRAVO and CRUISE who
crossed over to receive ranibizumab 0.5 mg PRN during the
observation period did not perform as well during their ﬁrst 6
months of ranibizumab PRN treatment as those patients who
received monthly ranibizumab at the start of the study. The
median time to the ﬁrst 15-letter or more gain was more than
6 months in the sham crossover patients compared with less
than 6 months in patients who received monthly ranibizumab.
The cumulative percentage of sham crossover patients who
ever gained 15 or more ETDRS letters during ranibizumab
0.5 mg PRN treatment was 10.8% in BRAVO (these patients
could also receive rescue laser therapy) and 26.2% in
CRUISE, compared with a cumulative percentage of more
than 50% among all patients who were randomized to receive
monthly ranibizumab during the ﬁrst 6 months of the study.
This was an unplanned post hoc analysis; thus, the results
could have reached statistical signiﬁcance because of chance
alone and should be interpreted with caution. The results of
this retrospective analysis suggest that delaying treatment
from the time of initial diagnosis may lead to less visual
gain, or perhaps some loss of vision, that may not be
recovered after treatment starts. Similar effects on vision
have been observed in patients with age-related macular
degeneration and diabetic macular edema; delays in starting
treatment after a conﬁrmed initial diagnosis seem to be
associated with poorer visual outcomes.14,15 However, it
should be noted that the sham crossover patients did not
receive an aggressive monthly loading dose of treatment
during the observation period, receiving criteria-based PRN
treatment instead, and it is not clear how this might have
affected subsequent vision gains. Furthermore, the vision in
patients receiving sham treatment improved during the ﬁrst
6 months of both studies, and by month 6, VA in these
patients was better than that of patients in the ranibizumab
groups at the start of the study. Consequently, analyzing the
crossover patients using month 6 as baseline would have
biased against these patients potentially gaining 15 letters or
more during the observation period. However, these limi-
tations aside, our results suggest that patients whose treat-
ment is delayed do less well than those who receive prompt
treatment upon diagnosis. It also seems that any deﬁcits in
vision gains resulting from delays in treatment are not
recovered after treatment starts. In this case, patients who
received initial sham treatment failed to show the same
gains in vision as the ranibizumab-treated groups by month
12 of the study. In clinical practice, patients diagnosed with
RVO may beneﬁt from initiating treatment earlier upon
diagnosis compared with delaying therapy.
In this analysis, we also investigated the association be-
tween CFT and VA. Data from BRAVO and CRUISE show
that treatment with ranibizumab reduced CFT and improved
VA simultaneously.5e8 Establishing the extent of the rela-
tionship between these 2 parameters may help to deﬁne the
most appropriate re-treatment criteria to maintain improve-
ments. Although several previous studies have examined this
association in age-related macular degeneration16e18 and
diabetic macular edema,19,20 there are limited data to date
from patients with RVO. A small study of CRVO patientsfailed to show an association.21 Conversely, a larger study
was able to show a modest correlation between ﬁnal VA
and ﬁnal CFT at the end of a 12-month bevacizumab treat-
ment in both patients with CRVO and patients with BRVO
and a modest correlation between VA and CFT improvement
over time only in patients with BRVO,22 whereas a recent
retrospective study of 53 patients demonstrated an inverse
correlation between foveal thickness and VA.23 The present
analysis suggested a trend for an association between lower
CFT measurements and higher VA letter scores as well as an
association between change from baseline values in both
BRVO and CRVO. However, these associations were
modest, and not all patients had simultaneous improvements
in both CFT and VA. Furthermore, the correlation appeared
to be stronger at month 3 and month 6 than at month 12,
suggesting a possible relationship with disease activity that
reduces after stabilization occurs. The lack of a strong
association between the 2 measures is consistent with
available data and may indicate that, at least in a subset of
patients, reducing macular edema may not be sufﬁcient to
improve VA, whereas, conversely, clinically signiﬁcant VA
improvements are still possible despite persistent edema in
some patients. The relationship between anatomic changes
and vision outcomes requires further investigation.
Data from this post hoc analysis showed that most patients
treated with monthly ranibizumab in BRAVO and CRUISE
ﬁrst achieved clinically signiﬁcant VA gains of 15 letters or
more as early as 7 days after injection through to 6 months,
which was largely maintained using PRN treatment. Patients
who initially received sham treatment plus rescue laser in the
BRAVO study orwho received sham treatment in the CRUISE
study demonstrated vision gains with subsequent treatment
with ranibizumab 0.5 mg PRN during the observation period
but did not achieve the same response levels to treatment as the
groups initially randomized to ranibizumab. Starting treatment
as soon as possible after diagnosis therefore may provide the
greatest beneﬁts in terms of vision gains. Further prospective
clinical studies and sensitivity and cost-beneﬁt analyses may
be required to conﬁrm the beneﬁts of early antievascular
endothelial growth factor therapy in patients diagnosed with
BRVO or CRVO observed in these trials.
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